Overview

A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite DMARD (Disease-modifying antirheumatic drugs) therapy. Another objective is to evaluate the pharmacokinetics of golimumab.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.
Collaborator:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Antibodies, Monoclonal
Golimumab